
|Videos|April 26, 2011
Phase II AMG 386 and Paclitaxel Combination Trial
Author(s)Beth Y. Karlan MD
Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Advertisement
Beth Y. Karlan MD Director at Cedars-Sinai Women's Cancer Research Institute Provides an Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5







































































